The mean level of serum COMP of the metastatic patients (n = 176) was 10.72 U/L, twice as high compared to 5.22 U/L of the patients with early breast cancer (n = 57), with very strong statistical significance (p < 0.001, Figure 2). The gene discussed is COMP; the disease is breast carcinoma.